Ari VanderWalde
Directeur Technique/Scientifique/R&D chez Vector Oncology Solutions LLC
Provenance du réseau au premier degré de Ari VanderWalde
Entité | Type d'entité | Industrie | |
---|---|---|---|
Vector Oncology Solutions LLC
Vector Oncology Solutions LLC Investment ManagersFinance Founded in 2001 by John McFarland, Vector Oncology Solutions LLC is a leader of oncology specific biopharmaceutical development and commercial outsourcing services. The firm was formerly known as Acorn Research LLC and is located in Memphis, Tennessee. Their novel data repository comprised of aggregated clinical (EMR), patient reported outcomes, genomic, physician notes and billing data powers a broad array of retrospective and prospective HEOR projects that provide an understanding of current practices in oncology care. Vector Oncology also provides comprehensive clinical trial services with specific expertise in supporting and accelerating early phase clinical trials and providing real-world late stage services.
1
| Private Company | Investment Managers | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Ari VanderWalde via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
Watermill Ventures Ltd.
Watermill Ventures Ltd. Investment ManagersFinance Watermill Ventures is a private equity firm founded by Steven E. Karol in 2004,headquarters in US. | Investment Managers | Corporate Officer/Principal | |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Masters Business Admin | |
Dartmouth College | College/University | Undergraduate Degree | |
Oncology Development Partners LLC
Oncology Development Partners LLC Miscellaneous Commercial ServicesCommercial Services Oncology Development Partners LLC is an American company that focuses on research and development in the field of oncology. | Miscellaneous Commercial Services | President | |
United BioSource Corp.
United BioSource Corp. Miscellaneous Commercial ServicesCommercial Services United BioSource Corp. is a scientific and medical affairs organization that partners with life science companies to develop and commercialize their products. The company is involved in pre- and post-approval product development; pricing, coverage, reimbursement, and access strategies; and medical publication and communications. United BioSource Corp. was founded by Ethan D. Leder and Mark P. Cleinin in 2003 and is headquartered in Chevy Chase, MD. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Bain & Co., Inc.
Bain & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Bain & Co., Inc. provides management consulting services. It offers advisory services to the companies on their critical issues and opportunities: strategy, marketing, organization, operations, technology and mergers and acquisitions, across all industries and geographies. The company was founded in 1973 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Vermont Academy
Vermont Academy Other Consumer ServicesConsumer Services Vermont Academy operates as a school. The firm’s courses include advanced physics, environmental science, advanced biology, biochemistry and more. The company was founded in 1872 and is headquartered in Saxtons River, VT. | Other Consumer Services | Director/Board Member | |
Autem Therapeutics
Autem Therapeutics Medical/Nursing ServicesHealth Services Autem Therapeutics is a privately held bioelectric and oncology therapeutic company based in Hanover, NH, USA. The company is developing a non-invasive and non-toxic oncology treatment platform targeting liver cancer and other solid tumor cancers. Autemsys™ therapy, the company's breakthrough treatment, delivers personalized, amplitude-modulated electromagnetic frequencies that show promise in shrinking cancerous tumors, enhancing quality of life, and extending survival in early and advanced stage cancer patient populations. The company has received FDA breakthrough designation for its Autemsys™ therapy for the treatment of advanced HCC patients. Autem Therapeutics anticipates submitting an FDA investigational device exemption (IDE) to initiate FDA pivotal clinical trials in late 2022 or early 2023. The company was founded by Frederico Costa and Michael A. Choukas, and Michael A. Choukas has been the CEO since incorporation. | Medical/Nursing Services | Chief Executive Officer |
Statistiques
Internationale
Etats-Unis | 11 |
Sectorielle
Commercial Services | 6 |
Consumer Services | 4 |
Finance | 2 |
Health Services | 2 |
Opérationnelle
Corporate Officer/Principal | 4 |
Founder | 2 |
Chief Executive Officer | 2 |
Masters Business Admin | 1 |
Undergraduate Degree | 1 |
Relations les plus connectées
Insiders | |
---|---|
Michael Choukas | 11 |
- Bourse
- Insiders
- Ari VanderWalde
- Connexions Sociétés